Dr. Elizabeth Yurth is the Co-Founder and Medical Director of Boulder Longevity Institute. Dr. Yurth is double-Board Certified in Physical Medicine & Rehabilitation and Anti-Aging/Regenerative Medicine. She has a Stanford-affiliated Fellowship in Sports and Spine Medicine, and a dual-Fellowship in Anti-Aging and Regenerative Medicine (FAARM) and Anti-Aging, Regenerative and Functional Medicine (FAARFM). As an athlete herself who has dealt with numerous injuries, Dr. Yurth is thrilled to share with her clients all the innovative, life-changing treatments that are on the cutting-edge of medicine
Article
Dec 16, 2025
Elizabeth Yurth, MD
Myriah Werne
RELATED RESOURCES
Continue exploring related topics.
VIEW ALL
SSRP Institute
May 6, 2026
Nutrition Education for Physicians and Medical Students
HEADLINE SCIENCE MAY 6, 2026 —Earlier in March, the U.S. Department of Health and Human Services (HHS) and the U.S. Department of Education announced an initiative to emphasize nutrition at the nation’s top medical schools. Reflecting U.S. Health and Human Services Secretary Robert Kennedy’s commitment to preventative medicine, this initiative will require “meaningful nutrition training” […]
READ NEWS
VIDEO
Cellular Medicine Mondays
May 4, 2026
Ep. 086 - May '26
Preview Only
Dr. Seeds’ Office Hours – Episode 086
1. SSRI tapering resistance, anxiety during weaning (0:40)
2. Progressive multifocal dystonia (13:27)
3. Complex type 2 diabetes case in a lean, athletic patient (28:32)
Preview Only — Become a member for full access
SSRP Institute
Apr 29, 2026
New ACC and AHA Cholesterol Management Guidelines
HEADLINE SCIENCE APRIL 29, 2026 – The American College of Cardiology (ACC) and American Heart Association (AHA) have updated their cholesterol management guidelines, advocating for earlier and more aggressive intervention based on the understanding that cumulative lifetime exposure to high LDL-C drives atherosclerotic cardiovascular disease (ASCVD) risk. The guidelines aim to standardize care for dyslipidemia […]
READ NEWS
VIDEO
Cellular Medicine Mondays
Apr 27, 2026
Ep. 085 - Peptide Pharmacokinetics
Preview Only
Dissecting Protocols – Episode 085
Peptide Pharmacokinetics
Dissecting Protocols, Dr. Seeds breaks down the reasoning behind SubQ vs. IM peptide administration. From pharmacokinetic considerations to the growing misuse of combining peptides with oil-based medications in the same syringe, this discussion helps clarify proper application and safety considerations.
Preview Only — Become a member for full access
William Seeds, MD
Apr 21, 2026
A Review of Circadian Processes and Evidence-Based Interventions to Improve Sleep
Introduction In March of this year, I did a Rabbit Hole (Episode 079) in which I discussed a number of trends marketed to the wider public promising sleep improvement. As you know, a huge swath of the population suffers from sleep disturbance. According to the NIH, approximately 30% to 40% of US adults report sleep […]
READ ARTICLE
VIDEO
Cellular Medicine Mondays
Apr 20, 2026
Ep. 084 - The Cellular Impact of UVA vs. UVB Light (Part 2)
Preview Only
Rabbit Holes – Episode 084
The Cellular Impact of UVA vs. UVB Light (Part 2)
Dr. Seeds continues this Rabbit Hole on UVA vs. UVB light in Part 2, covering oxidative stress, skin aging, vitamin D synthesis, and the risks of tanning beds. A helpful look at why not all UV exposure works the same, why that distinction matters, and how it shapes both skin health and cellular function
Catch Part 1 (Rabbit Holes – Ep. 081) HERE
Preview Only — Become a member for full access
SSRP Institute
Apr 15, 2026
FDA Announces Change in Status of 12 Peptides
BREAKING NEWS APRIL 15, 2026 – In a welcome announcement to the SSRP community, the FDA reported today that it will imminently remove the following bulk drug substances from category 2: BPC-157, LL-37, DiHexa, DSIP, Epitalon, *GHK-Cu (injectable only), KPV, PEG-MGF, Melanotan II, MOTs-C, Semax, and TB-500. Originally nominated for Category 2 (Bulk Substances that […]
READ NEWS
VIDEO
Cellular Medicine Mondays
Apr 13, 2026
Ep. 083 - Safety of Low-Dose Oral Minoxidil for Hair Loss: A Multicenter Study of 1404 Patients
Preview Only
Journal Club – Episode 083
Safety of Low-Dose Oral Minoxidil for Hair Loss: A Multicenter Study of 1404 Patients
Dr. Seeds discusses this article on low dose minoxidil for hair loss and shares why a lower, slower dosing approach may lead to better outcomes. He also reviews key safety considerations, side effects, and practical dosing insights for both men and women. (Article Link)
Preview Only — Become a member for full access
SSRP Institute
Apr 9, 2026
SSRP Institute Welcomes StemWave as New Trusted Partner
PARTNER ANNOUNCEMENT WILLOUGHBY, Ohio, [April 9, 2026] — The SSRP Institute announces that StemWave has joined its Trusted Partner Network following nomination and completion of the SSRP’s internal review process. StemWave provides an FDA-listed, non-invasive acoustic wave therapy platform used in musculoskeletal care. The technology delivers focused mechanical energy to targeted tissues, supporting improved circulation, […]
READ NEWS
VIDEO
Cellular Medicine Mondays
Apr 6, 2026
Ep. 082 - April '26
Preview Only
Dr. Seeds’ Office Hours – Episode 082
1. Idiopathic pulmonary fibrosis in patient already receiving immunosuppressive therapy (1:01)
2. Peptide considerations for a 14-year-old diagnosed with “internal preoccupation” (28:44)
3. Patient with hypermobility, mitochondrial dysfunction, and mast cell activation after COVID (39:48)
Preview Only — Become a member for full access